Home Cart Sign in  
Chemical Structure| 17795-21-0 Chemical Structure| 17795-21-0

Structure of Allopurinol sodium
CAS No.: 17795-21-0

Chemical Structure| 17795-21-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Allopurinol sodium is a xanthine oxidase inhibitor with an IC50 of 7.82±0.12 μM.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Allopurinol sodium

CAS No. :17795-21-0
Formula : C5H3N4NaO
M.W : 158.09
SMILES Code : [O-]C1=C2C(NN=C2)=NC=N1.[Na+]
MDL No. :MFCD12965022
InChI Key :PTJRZVJXXNYNLN-UHFFFAOYSA-M
Pubchem ID :23662349

Safety of Allopurinol sodium

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Description
Allopurinol sodium is a highly effective and orally active inhibitor of xanthine oxidase, with an IC50 ranging from 0.2 to 50 μM. It is commonly utilized in the study of hyperuricemia and gout. Beyond its primary application, Allopurinol sodium is known to decrease the expression of HIF-1α and HIF-2α proteins, exhibiting potential in reducing hypoxia-induced factors. Additionally, it has demonstrated antidepressant, anti-nociceptive, and anti-leishmanial activities[1].[2].[3].[4].[5].

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse aortic endothelial cells 100 μmol/L 4 hours To investigate the effect of allopurinol on MP-mediated oxidative stress in endothelial cells, results showed that allopurinol had no significant effect on MP-mediated ROS production. PMC3487329
THP-1 human myeloid leukemia cells 250 μg/ml 1 hour pre-treatment Pre-treatment with allopurinol attenuated XOD activation/UA production and significantly decreased phospho-S2448 mTOR levels while increasing T2446 phosphorylation. PMC4158321

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice Wild-type and AMPD2 knockout mice Drinking water 1.1 mM 30 weeks Allopurinol significantly reduced plasma and intrahepatic uric acid levels in MSG + IMP-treated mice and attenuated weight gain and features of metabolic syndrome. PMC9987717
Mice Endotoxin-induced bacterial translocation model Oral gavage 50 mg/kg Once at 48 and 24 hours before To investigate the effect of allopurinol on endotoxin-induced bacterial translocation. Results showed that allopurinol significantly reduced endotoxin-induced bacterial translocation and mucosal injury. PMC303949
C57BL6/J male mice Western diet-induced obesity model Drinking water administration 125 mg/L Continued for 16 weeks XO inhibition significantly attenuated WD-induced increases in plasma uric acid, vascular XO activity and oxidative stress, in concert with reductions in proteinuria. Further, XO inhibition prevented WD-induced increases in aortic EnNaC expression and associated endothelial and subendothelial stiffness. XO inhibition also reduced vascular pro-inflammatory and maladaptive immune responses induced by consumption of a WD. PMC5577816
CD1 male mice Systemic PGN injection model Systemic injection 1 mg/kg Single injection, sampled 4 hours post-injection PGN induced XOD activity in blood cells and liver in vivo, along with increased UA levels in blood plasma and liver, and upregulated PI-3K/mTOR pathway activity. PMC4158321
C57BL/6 mice Hyperuricaemia model Oral 5 mg/kg 7 consecutive days Reduced serum uric acid levels and inhibited liver xanthine oxidase activity PMC7534190
Mice Hypertension model Intraperitoneal injection 100 mg/kg Inhibition of xanthine-oxido-reductase prevented blood flow recovery in the ischemic hind-limb of hypertensive mice treated with sodium nitrite PMC3514594

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

6.33mL

1.27mL

0.63mL

31.63mL

6.33mL

3.16mL

63.26mL

12.65mL

6.33mL

References

 

Historical Records

Categories